Results & Financial lifeHealthcare - Pharma - Biotech
Inside Information / Other news releases
16/11/2026 07:30
AMFImmediate publication
o Extended circulation time in pigs, consistent with once-monthly dosing in humans o Body weight reduction over 26 days comparable to that of semaglutide reference in obese rats, with a dose-dependent effect
PRESS RELEASE
Lyon, November 16, 2026
ADOCIA Presents Preclinical Data at
ObesityWeek® 2026 Confirming the Potential of
AdoXLong™ for Monthly Injections of Peptides
- Key results on AdoXLong™ applied to semaglutide presented at ObesityWeek®:
o Extended circulation time in pigs, consistent with once-monthly dosing in humans o Body weight reduction over 26 days comparable to that of semaglutide reference in obese rats, with a dose-dependent effect
- New positive in vitro results on AdoXLong™ applied to retatrutide
7:30 am CET - Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of metabolic diseases including diabetes and obesity, today announces the presentation of preclinical data in poster format on its AdoXLong™ platform applied to semaglutide, AdoXL Sema, at ObesityWeek® 2026, taking place in Washington, USA, November 14-17, 2026.
The poster is titled “AdoXLong: A Long-Acting Peptide Platform Enabling Once-Monthly Administration of Incretins”. The data presented supports a once-monthly AdoXL Sema administration in humans.
- In vitro, the intrinsic relative potency and efficacy of AdoXL Sema are well preserved. A decrease in AdoXL Sema activity is observed in the presence of HSA, confirming its high affinity for albumin.
- After subcutaneous administration in rats, AdoXL Sema demonstrates a prolonged half-life of 32 h, corresponding to more than 4-fold the half-life of semaglutide.
- After intravenous (IV) and subcutaneous (SC) administration in farm pigs, AdoXL Sema demonstrates a prolonged half-life of 153 h (IV) and 159 h (SC), corresponding to more than 3-fold the half-life of semaglutide1. This is associated with a high bioavailability (>90%).
- At a dose of 30 nmol/kg, the reduction in body weight gain is comparable to that observed with semaglutide, with a maximal body weight decrease of approximately 5-6% from baseline.
In parallel, new positive in vitro results on AdoXLong applied to retatrutide have been obtained, further validating the platform nature of AdoXLong . In vitro results for AdoXL retatrutide show preserved activity at all three receptors targeted by this peptide (GLP-1, GIP and glucagon). As with AdoXL Sema, AdoXL retatrutide is expected to show an extended in vivo circulation time compared with retatrutide.
“AdoXLong aims to deliver the convenience of once-monthly dosing while remaining compatible with the standard injection devices already used by patients receiving today’s weekly therapies. These promising preclinical results, together with those obtained with AdoXLong applied to retatrutide, strengthen our confidence in this platform’s potential. We intend to continue its development toward clinical evaluation, while favoring partnerships with pharmaceutical companies to apply AdoXLong to their peptides,” said Olivier Soula, Chief Executive Officer and Co-Founder of Adocia.